Conference/Events
|
17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< TVTX Travere Therapeutics - 02/02/21
- Ligand says entitled to $5.9M milestone on Travere application submission
- 01/12/21
- Travere Therapeutics receives orphan drug designation for sparsentan from FDA
- 01/11/21
- Travere Therapeutics announces anticipated upcoming milestones
- 11/30/20
- Travere Therapeutics completes patient enrollment in DUPLEX Study
TAK Takeda Pharmaceutical - 02/10/21
- Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan
- 01/28/21
- Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion
- 01/21/21
- Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine
- 12/18/20
- Takeda confirms FDA approval of sNDA for Iclusig
- 02/09/21
- Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo
- 02/05/21
- Sanofi presents amended protocols in fitusiran clinical studies
- 01/27/21
- Sanofi's priority is to continue to develop two Covid vaccine candidates
- 01/27/21
- Sanofi to provide support to BioNTech in manufacturing Covid vaccine
SGTX Sigilon Therapeutics - 12/17/20
- Sigilon Therapeutics receives Orphan Drug designation for SIG-005
- 12/14/20
- Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19
- 02/10/21
- Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated
- 01/21/21
- Ultragenyx announces FDA clearance of IND application for UX701
- 01/11/21
- Ultragenyx announces 2021 milestones
- 01/11/21
- Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31
- 02/10/21
- BioNTech provides update on vaccine production at Marburg manufacturing site
- 02/08/21
- Longevity announces 4D trial collaboration with Pfizer and Merck KGaA
- 02/05/21
- Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027
- 02/02/21
- Pfizer sees FY21 revenue from BNT162b2 approximately $15B
- 02/08/21
- Passage Bio's IND application for Krabbe disease candidate cleared by FDA
- 01/28/21
- Passage Bio annoounces FDA IND clearance for PBFT02
- 01/11/21
- Passage Bio says PBGM01 entering clinic to study safety, efficacy
- 01/11/21
- Passage Bio announces corporate outlook
ORTX Orchard Therapeutics - 02/09/21
- Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome
- 02/05/21
- Orchard Therapeutics announces $150M strategic financing
- 01/29/21
- Orchard Therapeutics appoints Braden Parker as CCO
- 01/19/21
- Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN
- 12/31/20
- CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021
- 12/07/20
- CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval
- 11/11/20
- CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment
- 11/09/20
- Orphazyme submits arimoclomol MAA to EMA
- 01/13/21
- Pacific Biosciences, Invitae to develop genome sequencing platform
- 01/11/21
- Invitae falls -10.2%
- 12/17/20
- Invitae falls -7.4%
- 12/17/20
- Invitae introduces routine exome reanalysis
- 02/11/21
- Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa
- 02/11/21
- Amicus trading resumes
- 02/11/21
- Amicus trading halted, news pending
- 02/08/21
- Amicus announces preclinical Fabry disease gene therapy data
- 02/08/21
- Homology reports first presentation of data from IND-enabling studies of HMI-203
- 01/12/21
- Pfizer invests $120M in four clinical-stage biotech companies
- 01/06/21
- Homology Medicines announces plans for three clinical programs in 2021
- 11/19/20
- Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer
- 01/20/21
- Denali Therapeutics CFO sells 50K shares of common stock
- 01/11/21
- Denali Therapeutics appoints Nancy Thornberry to board of directors
- 01/08/21
- Denali plans to file IND or CTA for DNL919 in late 2021/early 2022
- 01/08/21
- Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021
- 01/10/21
- BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study
- 12/21/20
- BioMarin reports results of Phase 3 extension study of vosoritide
- 11/17/20
- BioMarin and Deep Genomics enter into preclinical collaboration
- 11/09/20
- BioMarin expands clinical program for vosoritide with new studies
- 02/08/21
- Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi
- 01/19/21
- Avrobio appoints Diana Escolar as CMO
- 11/17/20
- Avrobio announces new data in clinical programs
- 10/05/20
- Avrobio to collaborate with University of Manchester for MPS II therapy
- 01/25/21
- Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting
- 12/21/20
- Abeona announces acceptance of late-breaker abstracts for WORLDSymposium
- 10/27/20
- Abeona Therapeutics names of Michael Amoroso as COO
- 10/06/20
- Abeona forms special committee to oversee strategic direction, leadership, ops
- 11/25/20 H.C. Wainwright
- Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
- 11/11/20 B. Riley
- Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
- 11/10/20 Cantor Fitzgerald
- Cantor upgrades Abeona to Overweight with shares trading near cash
- 11/10/20 Cantor Fitzgerald
- Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- 11/18/20 Mizuho
- Avrobio price target raised to $43 from $35 at Mizuho
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Avrobio initiated with a Buy at Berenberg
- 03/31/20 H.C. Wainwright
- Avrobio downgraded to Neutral from Buy at H.C. Wainwright
- 01/29/21 Jefferies
- Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
- 01/11/21 Baird
- BioMarin price target raised to $110 from $100 at Baird
- 12/21/20 Piper Sandler
- BioMarin data today should ease approvability concerns, says Piper Sandler
- 12/17/20 JPMorgan
- BioMarin remains 'highest conviction name' at JPMorgan
- 02/10/21
- Fly Intel: Top five analyst upgrades
- 02/10/21 Cantor Fitzgerald
- Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- 11/11/20 JPMorgan
- Denali Therapeutics price target raised to $65 from $45 at JPMorgan
- 11/11/20 H.C. Wainwright
- Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
- 12/14/20 H.C. Wainwright
- Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
- 11/08/20 Oppenheimer
- Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
- 08/11/20 Oppenheimer
- Homology Medicines price target lowered to $27 from $32 at Oppenheimer
- 08/11/20 H.C. Wainwright
- Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
- 02/12/21 Cantor Fitzgerald
- Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
- 02/12/21 JPMorgan
- Amicus downgraded to Neutral from Overweight at JPMorgan
- 01/22/21 JPMorgan
- Amicus remains top idea into 'meaningful catalyst' at JPMorgan
- 01/04/21 Cowen
- Amicus could move 30%-40% on Pompe study data, says Cowen
- 02/10/21 Morgan Stanley
- Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley
- 02/08/21 JPMorgan
- Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
- 10/29/20 Morgan Stanley
- Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
- 10/28/20 JPMorgan
- Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform on valuation at Oppenheimer
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform from Outperform at Oppenheimer
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral on valuation at Ladenburg
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral from Buy at Ladenburg
- 10/26/20 Guggenheim
- Orphazyme initiated with a Buy at Guggenheim
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics - 01/07/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 01/06/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 09/14/20 Oppenheimer
- Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
- 09/10/20 SMBC Nikko
- Orchard Therapeutics initiated with an Outperform at SMBC Nikko
- 02/04/21
- Fly Intel: Top five analyst initiations
- 02/04/21 Guggenheim
- Passage Bio initiated with a Buy at Guggenheim
- 01/25/21 Citi
- Citi upgrades Passage Bio to Buy after pullback and ahead of data
- 01/25/21 Citi
- Passage Bio upgraded to Buy from Neutral at Citi
- 02/10/21 KeyBanc
- Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
- 02/04/21 DZ Bank
- Pfizer upgraded to Buy from Hold at DZ Bank
- 02/03/21 Mizuho
- Pfizer price target lowered to $42 from $44 at Mizuho
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 02/11/21 Piper Sandler
- Ultragenyx price target raised to $170 from $165 at Piper Sandler
- 01/25/21 Credit Suisse
- Ultragenyx price target raised to $99 from $64 at Credit Suisse
- 01/11/21 Baird
- Ultragenyx price target raised to $165 from $110 at Baird
- 01/11/21 Barclays
- Ultragenyx price target raised to $176 from $121 at Barclays
SGTX Sigilon Therapeutics - 12/29/20 Barclays
- Sigilon Therapeutics initiated with an Overweight at Barclays
- 12/29/20 Morgan Stanley
- Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
- 12/29/20 Jefferies
- Sigilon Therapeutics initiated with a Buy at Jefferies
- 02/10/21 Morgan Stanley
- Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
- 02/05/21 Piper Sandler
- Piper reiterates Overweight on Kymera after Sanofi capital markets day
- 01/19/21 UBS
- Sanofi price target lowered to EUR 99 from EUR 100 at UBS
- 01/15/21 Deutsche Bank
- Sanofi initiated with a Sell at Deutsche Bank
TAK Takeda Pharmaceutical - 01/29/21 Morgan Stanley
- Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
- 12/29/20 Needham
- Needham names Phathom Pharmaceuticals Top Pick for 2021
- 12/15/20 Needham
- Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
- 06/18/20 RBC Capital
- Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics - 02/03/21
- Travere Therapeutics price target raised to $48 from $33 at BMO Capital
- 02/03/21 Canaccord
- Travere Therapeutics price target raised to $51 from $28 at Canaccord
- 11/23/20 Evercore ISI
- Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics - 02/02/21
- Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study
- 01/11/21
- Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M
- 01/11/21
- Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M
- 02/05/21
- Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year
- 10/29/20
- Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year
- 02/11/21
- Ultragenyx backs FY21 revenue guidance range for Crysvita
- 02/11/21
- Ultragenyx backs FY21 revenue guidance range for Crysvita
- 02/11/21
- Ultragenyx reports Q4 EPS (37c), consensus ($1.16)
- 10/27/20
- Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27)
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer reports Q4 adjusted EPS 42c, consensus 48c
- 02/01/21
- Notable companies reporting before tomorrow's open
- 11/10/20
- Passage Bio reports Q3 EPS (63c), consensus (76c)
- 08/13/20
- Passage Bio reports Q2 EPS (60c), consensus (57c)
ORTX Orchard Therapeutics - 11/03/20
- Orchard Therapeutics reports Q3 EPS (20c), consensus (46c)
- 01/11/21
- Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M
- 01/11/21
- Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M
- 11/05/20
- Invitae reports Q3 non-GAAP EPS (62c), consensus (66c)
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 11/09/20
- Homology Medicines reports Q 3EPS (62c), consensus (80c)
- 11/05/20
- Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year
- 11/05/20
- BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B
- 11/05/20
- BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29
- 11/05/20
- Avrobio reports Q3 EPS ($1.01), consensus (81c)
- 11/09/20
- Abeona Therapeutics reports Q3 EPS (8c), consensus (15c)
|
Conference/Events
|
17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< TVTX Travere Therapeutics - 02/02/21
- Ligand says entitled to $5.9M milestone on Travere application submission
- 01/12/21
- Travere Therapeutics receives orphan drug designation for sparsentan from FDA
- 01/11/21
- Travere Therapeutics announces anticipated upcoming milestones
- 11/30/20
- Travere Therapeutics completes patient enrollment in DUPLEX Study
TAK Takeda Pharmaceutical - 02/10/21
- Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan
- 01/28/21
- Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion
- 01/21/21
- Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine
- 12/18/20
- Takeda confirms FDA approval of sNDA for Iclusig
- 02/09/21
- Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo
- 02/05/21
- Sanofi presents amended protocols in fitusiran clinical studies
- 01/27/21
- Sanofi's priority is to continue to develop two Covid vaccine candidates
- 01/27/21
- Sanofi to provide support to BioNTech in manufacturing Covid vaccine
SGTX Sigilon Therapeutics - 12/17/20
- Sigilon Therapeutics receives Orphan Drug designation for SIG-005
- 12/14/20
- Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19
- 02/10/21
- Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated
- 01/21/21
- Ultragenyx announces FDA clearance of IND application for UX701
- 01/11/21
- Ultragenyx announces 2021 milestones
- 01/11/21
- Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31
- 02/10/21
- BioNTech provides update on vaccine production at Marburg manufacturing site
- 02/08/21
- Longevity announces 4D trial collaboration with Pfizer and Merck KGaA
- 02/05/21
- Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027
- 02/02/21
- Pfizer sees FY21 revenue from BNT162b2 approximately $15B
- 02/08/21
- Passage Bio's IND application for Krabbe disease candidate cleared by FDA
- 01/28/21
- Passage Bio annoounces FDA IND clearance for PBFT02
- 01/11/21
- Passage Bio says PBGM01 entering clinic to study safety, efficacy
- 01/11/21
- Passage Bio announces corporate outlook
ORTX Orchard Therapeutics - 02/09/21
- Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome
- 02/05/21
- Orchard Therapeutics announces $150M strategic financing
- 01/29/21
- Orchard Therapeutics appoints Braden Parker as CCO
- 01/19/21
- Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN
- 12/31/20
- CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021
- 12/07/20
- CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval
- 11/11/20
- CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment
- 11/09/20
- Orphazyme submits arimoclomol MAA to EMA
- 01/13/21
- Pacific Biosciences, Invitae to develop genome sequencing platform
- 01/11/21
- Invitae falls -10.2%
- 12/17/20
- Invitae falls -7.4%
- 12/17/20
- Invitae introduces routine exome reanalysis
- 02/08/21
- Amicus announces preclinical Fabry disease gene therapy data
- 02/08/21
- Amicus reports 'positive' initial clinical data for CLN3 program
- 01/11/21
- Amicus announces 2021 upcoming milestones
- 01/11/21
- Amicus announces 2021 strategic priorities
- 02/08/21
- Homology reports first presentation of data from IND-enabling studies of HMI-203
- 01/12/21
- Pfizer invests $120M in four clinical-stage biotech companies
- 01/06/21
- Homology Medicines announces plans for three clinical programs in 2021
- 11/19/20
- Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer
- 01/20/21
- Denali Therapeutics CFO sells 50K shares of common stock
- 01/11/21
- Denali Therapeutics appoints Nancy Thornberry to board of directors
- 01/08/21
- Denali plans to file IND or CTA for DNL919 in late 2021/early 2022
- 01/08/21
- Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021
- 01/10/21
- BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study
- 12/21/20
- BioMarin reports results of Phase 3 extension study of vosoritide
- 11/17/20
- BioMarin and Deep Genomics enter into preclinical collaboration
- 11/09/20
- BioMarin expands clinical program for vosoritide with new studies
- 02/08/21
- Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi
- 01/19/21
- Avrobio appoints Diana Escolar as CMO
- 11/17/20
- Avrobio announces new data in clinical programs
- 10/05/20
- Avrobio to collaborate with University of Manchester for MPS II therapy
- 01/25/21
- Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting
- 12/21/20
- Abeona announces acceptance of late-breaker abstracts for WORLDSymposium
- 10/27/20
- Abeona Therapeutics names of Michael Amoroso as COO
- 10/06/20
- Abeona forms special committee to oversee strategic direction, leadership, ops
- 11/25/20 H.C. Wainwright
- Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
- 11/11/20 B. Riley
- Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
- 11/10/20 Cantor Fitzgerald
- Cantor upgrades Abeona to Overweight with shares trading near cash
- 11/10/20 Cantor Fitzgerald
- Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- 11/18/20 Mizuho
- Avrobio price target raised to $43 from $35 at Mizuho
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Avrobio initiated with a Buy at Berenberg
- 03/31/20 H.C. Wainwright
- Avrobio downgraded to Neutral from Buy at H.C. Wainwright
- 01/29/21 Jefferies
- Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
- 01/11/21 Baird
- BioMarin price target raised to $110 from $100 at Baird
- 12/21/20 Piper Sandler
- BioMarin data today should ease approvability concerns, says Piper Sandler
- 12/17/20 JPMorgan
- BioMarin remains 'highest conviction name' at JPMorgan
- 02/10/21
- Fly Intel: Top five analyst upgrades
- 02/10/21 Cantor Fitzgerald
- Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- 11/11/20 JPMorgan
- Denali Therapeutics price target raised to $65 from $45 at JPMorgan
- 11/11/20 H.C. Wainwright
- Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
- 12/14/20 H.C. Wainwright
- Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
- 11/08/20 Oppenheimer
- Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
- 08/11/20 Oppenheimer
- Homology Medicines price target lowered to $27 from $32 at Oppenheimer
- 08/11/20 H.C. Wainwright
- Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
- 01/22/21 JPMorgan
- Amicus remains top idea into 'meaningful catalyst' at JPMorgan
- 01/04/21 Cowen
- Amicus could move 30%-40% on Pompe study data, says Cowen
- 12/28/20 Cantor Fitzgerald
- Amicus assumed with an Overweight at Cantor Fitzgerald
- 12/14/20 JPMorgan
- JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
- 02/10/21 Morgan Stanley
- Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley
- 02/08/21 JPMorgan
- Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
- 10/29/20 Morgan Stanley
- Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
- 10/28/20 JPMorgan
- Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform on valuation at Oppenheimer
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform from Outperform at Oppenheimer
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral on valuation at Ladenburg
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral from Buy at Ladenburg
- 10/26/20 Guggenheim
- Orphazyme initiated with a Buy at Guggenheim
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics - 01/07/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 01/06/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 09/14/20 Oppenheimer
- Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
- 09/10/20 SMBC Nikko
- Orchard Therapeutics initiated with an Outperform at SMBC Nikko
- 02/04/21
- Fly Intel: Top five analyst initiations
- 02/04/21 Guggenheim
- Passage Bio initiated with a Buy at Guggenheim
- 01/25/21 Citi
- Citi upgrades Passage Bio to Buy after pullback and ahead of data
- 01/25/21 Citi
- Passage Bio upgraded to Buy from Neutral at Citi
- 02/10/21 KeyBanc
- Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
- 02/04/21 DZ Bank
- Pfizer upgraded to Buy from Hold at DZ Bank
- 02/03/21 Mizuho
- Pfizer price target lowered to $42 from $44 at Mizuho
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 01/25/21 Credit Suisse
- Ultragenyx price target raised to $99 from $64 at Credit Suisse
- 01/11/21 Baird
- Ultragenyx price target raised to $165 from $110 at Baird
- 01/11/21 Barclays
- Ultragenyx price target raised to $176 from $121 at Barclays
- 01/08/21 Piper Sandler
- Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics - 12/29/20 Barclays
- Sigilon Therapeutics initiated with an Overweight at Barclays
- 12/29/20 Morgan Stanley
- Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
- 12/29/20 Jefferies
- Sigilon Therapeutics initiated with a Buy at Jefferies
- 02/10/21 Morgan Stanley
- Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
- 02/05/21 Piper Sandler
- Piper reiterates Overweight on Kymera after Sanofi capital markets day
- 01/19/21 UBS
- Sanofi price target lowered to EUR 99 from EUR 100 at UBS
- 01/15/21 Deutsche Bank
- Sanofi initiated with a Sell at Deutsche Bank
TAK Takeda Pharmaceutical - 01/29/21 Morgan Stanley
- Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
- 12/29/20 Needham
- Needham names Phathom Pharmaceuticals Top Pick for 2021
- 12/15/20 Needham
- Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
- 06/18/20 RBC Capital
- Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics - 02/03/21
- Travere Therapeutics price target raised to $48 from $33 at BMO Capital
- 02/03/21 Canaccord
- Travere Therapeutics price target raised to $51 from $28 at Canaccord
- 11/23/20 Evercore ISI
- Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics - 02/02/21
- Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study
- 01/11/21
- Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M
- 01/11/21
- Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M
- 02/05/21
- Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year
- 10/29/20
- Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year
- 10/27/20
- Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27)
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer reports Q4 adjusted EPS 42c, consensus 48c
- 02/01/21
- Notable companies reporting before tomorrow's open
- 11/10/20
- Passage Bio reports Q3 EPS (63c), consensus (76c)
- 08/13/20
- Passage Bio reports Q2 EPS (60c), consensus (57c)
ORTX Orchard Therapeutics - 11/03/20
- Orchard Therapeutics reports Q3 EPS (20c), consensus (46c)
- 01/11/21
- Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M
- 01/11/21
- Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M
- 11/05/20
- Invitae reports Q3 non-GAAP EPS (62c), consensus (66c)
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 11/09/20
- Homology Medicines reports Q 3EPS (62c), consensus (80c)
- 11/05/20
- Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year
- 11/05/20
- BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B
- 11/05/20
- BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29
- 11/05/20
- Avrobio reports Q3 EPS ($1.01), consensus (81c)
- 11/09/20
- Abeona Therapeutics reports Q3 EPS (8c), consensus (15c)
|
Syndicate
|
Travere Therapeutics… Travere Therapeutics announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $150M of its common stock. BofA Securities, Jefferies and SVB Leerink are acting as the joint book-running managers for the offering. ShowHide Related Items >><< TVTX Travere Therapeutics - 02/02/21
- Ligand says entitled to $5.9M milestone on Travere application submission
- 01/12/21
- Travere Therapeutics receives orphan drug designation for sparsentan from FDA
- 01/11/21
- Travere Therapeutics announces anticipated upcoming milestones
- 11/30/20
- Travere Therapeutics completes patient enrollment in DUPLEX Study
TVTX Travere Therapeutics - 02/03/21
- Travere Therapeutics price target raised to $48 from $33 at BMO Capital
- 02/03/21 Canaccord
- Travere Therapeutics price target raised to $51 from $28 at Canaccord
- 11/23/20 Evercore ISI
- Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics - 02/02/21
- Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study
- 01/11/21
- Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M
- 01/11/21
- Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M
TVTX Travere Therapeutics - 11/19/20
- One new option listing and one option delisting on November 19th
|
Conference/Events
|
17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< TVTX Travere Therapeutics - 02/02/21
- Ligand says entitled to $5.9M milestone on Travere application submission
- 01/12/21
- Travere Therapeutics receives orphan drug designation for sparsentan from FDA
- 01/11/21
- Travere Therapeutics announces anticipated upcoming milestones
- 11/30/20
- Travere Therapeutics completes patient enrollment in DUPLEX Study
TAK Takeda Pharmaceutical - 01/28/21
- Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion
- 01/21/21
- Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine
- 12/18/20
- Takeda confirms FDA approval of sNDA for Iclusig
- 12/16/20
- Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment
- 02/09/21
- Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo
- 02/05/21
- Sanofi presents amended protocols in fitusiran clinical studies
- 01/27/21
- Sanofi's priority is to continue to develop two Covid vaccine candidates
- 01/27/21
- Sanofi to provide support to BioNTech in manufacturing Covid vaccine
SGTX Sigilon Therapeutics - 12/17/20
- Sigilon Therapeutics receives Orphan Drug designation for SIG-005
- 12/14/20
- Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19
- 01/21/21
- Ultragenyx announces FDA clearance of IND application for UX701
- 01/11/21
- Ultragenyx announces 2021 milestones
- 01/11/21
- Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31
- 01/11/21
- Ultragenyx sees 2021 Crysvita revenue $180M-$190M
- 02/08/21
- Longevity announces 4D trial collaboration with Pfizer and Merck KGaA
- 02/05/21
- Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027
- 02/02/21
- Pfizer sees FY21 revenue from BNT162b2 approximately $15B
- 02/01/21
- BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses
- 02/08/21
- Passage Bio's IND application for Krabbe disease candidate cleared by FDA
- 01/28/21
- Passage Bio annoounces FDA IND clearance for PBFT02
- 01/11/21
- Passage Bio says PBGM01 entering clinic to study safety, efficacy
- 01/11/21
- Passage Bio announces corporate outlook
ORTX Orchard Therapeutics - 02/09/21
- Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome
- 02/05/21
- Orchard Therapeutics announces $150M strategic financing
- 01/29/21
- Orchard Therapeutics appoints Braden Parker as CCO
- 01/19/21
- Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN
- 12/31/20
- CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021
- 12/07/20
- CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval
- 11/11/20
- CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment
- 11/09/20
- Orphazyme submits arimoclomol MAA to EMA
- 01/13/21
- Pacific Biosciences, Invitae to develop genome sequencing platform
- 01/11/21
- Invitae falls -10.2%
- 12/17/20
- Invitae falls -7.4%
- 12/17/20
- Invitae introduces routine exome reanalysis
- 02/08/21
- Amicus announces preclinical Fabry disease gene therapy data
- 02/08/21
- Amicus reports 'positive' initial clinical data for CLN3 program
- 01/11/21
- Amicus announces 2021 upcoming milestones
- 01/11/21
- Amicus announces 2021 strategic priorities
- 02/08/21
- Homology reports first presentation of data from IND-enabling studies of HMI-203
- 01/12/21
- Pfizer invests $120M in four clinical-stage biotech companies
- 01/06/21
- Homology Medicines announces plans for three clinical programs in 2021
- 11/19/20
- Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer
- 01/20/21
- Denali Therapeutics CFO sells 50K shares of common stock
- 01/11/21
- Denali Therapeutics appoints Nancy Thornberry to board of directors
- 01/08/21
- Denali plans to file IND or CTA for DNL919 in late 2021/early 2022
- 01/08/21
- Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021
- 01/10/21
- BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study
- 12/21/20
- BioMarin reports results of Phase 3 extension study of vosoritide
- 11/17/20
- BioMarin and Deep Genomics enter into preclinical collaboration
- 11/09/20
- BioMarin expands clinical program for vosoritide with new studies
- 02/08/21
- Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi
- 01/19/21
- Avrobio appoints Diana Escolar as CMO
- 11/17/20
- Avrobio announces new data in clinical programs
- 10/05/20
- Avrobio to collaborate with University of Manchester for MPS II therapy
- 01/25/21
- Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting
- 12/21/20
- Abeona announces acceptance of late-breaker abstracts for WORLDSymposium
- 10/27/20
- Abeona Therapeutics names of Michael Amoroso as COO
- 10/06/20
- Abeona forms special committee to oversee strategic direction, leadership, ops
- 11/25/20 H.C. Wainwright
- Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
- 11/11/20 B. Riley
- Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
- 11/10/20 Cantor Fitzgerald
- Cantor upgrades Abeona to Overweight with shares trading near cash
- 11/10/20 Cantor Fitzgerald
- Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- 11/18/20 Mizuho
- Avrobio price target raised to $43 from $35 at Mizuho
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Avrobio initiated with a Buy at Berenberg
- 03/31/20 H.C. Wainwright
- Avrobio downgraded to Neutral from Buy at H.C. Wainwright
- 01/29/21 Jefferies
- Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
- 01/11/21 Baird
- BioMarin price target raised to $110 from $100 at Baird
- 12/21/20 Piper Sandler
- BioMarin data today should ease approvability concerns, says Piper Sandler
- 12/17/20 JPMorgan
- BioMarin remains 'highest conviction name' at JPMorgan
- 11/11/20 JPMorgan
- Denali Therapeutics price target raised to $65 from $45 at JPMorgan
- 11/11/20 H.C. Wainwright
- Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
- 11/10/20 Goldman Sachs
- Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
- 11/06/20 H.C. Wainwright
- Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
- 12/14/20 H.C. Wainwright
- Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
- 11/08/20 Oppenheimer
- Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
- 08/11/20 Oppenheimer
- Homology Medicines price target lowered to $27 from $32 at Oppenheimer
- 08/11/20 H.C. Wainwright
- Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
- 01/22/21 JPMorgan
- Amicus remains top idea into 'meaningful catalyst' at JPMorgan
- 01/04/21 Cowen
- Amicus could move 30%-40% on Pompe study data, says Cowen
- 12/28/20 Cantor Fitzgerald
- Amicus assumed with an Overweight at Cantor Fitzgerald
- 12/14/20 JPMorgan
- JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
- 02/08/21 JPMorgan
- Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
- 10/29/20 Morgan Stanley
- Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
- 10/28/20 JPMorgan
- Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
- 10/28/20 Deutsche Bank
- Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform on valuation at Oppenheimer
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform from Outperform at Oppenheimer
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral on valuation at Ladenburg
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral from Buy at Ladenburg
- 10/26/20 Guggenheim
- Orphazyme initiated with a Buy at Guggenheim
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics - 01/07/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 01/06/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 09/14/20 Oppenheimer
- Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
- 09/10/20 SMBC Nikko
- Orchard Therapeutics initiated with an Outperform at SMBC Nikko
- 02/04/21
- Fly Intel: Top five analyst initiations
- 02/04/21 Guggenheim
- Passage Bio initiated with a Buy at Guggenheim
- 01/25/21 Citi
- Citi upgrades Passage Bio to Buy after pullback and ahead of data
- 01/25/21 Citi
- Passage Bio upgraded to Buy from Neutral at Citi
- 02/04/21 DZ Bank
- Pfizer upgraded to Buy from Hold at DZ Bank
- 02/03/21 Mizuho
- Pfizer price target lowered to $42 from $44 at Mizuho
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 01/29/21 Piper Sandler
- Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
- 01/25/21 Credit Suisse
- Ultragenyx price target raised to $99 from $64 at Credit Suisse
- 01/11/21 Baird
- Ultragenyx price target raised to $165 from $110 at Baird
- 01/11/21 Barclays
- Ultragenyx price target raised to $176 from $121 at Barclays
- 01/08/21 Piper Sandler
- Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics - 12/29/20 Barclays
- Sigilon Therapeutics initiated with an Overweight at Barclays
- 12/29/20 Morgan Stanley
- Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
- 12/29/20 Jefferies
- Sigilon Therapeutics initiated with a Buy at Jefferies
- 02/05/21 Piper Sandler
- Piper reiterates Overweight on Kymera after Sanofi capital markets day
- 01/19/21 UBS
- Sanofi price target lowered to EUR 99 from EUR 100 at UBS
- 01/15/21 Deutsche Bank
- Sanofi initiated with a Sell at Deutsche Bank
- 01/08/21 Morgan Stanley
- Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical - 01/29/21 Morgan Stanley
- Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
- 12/29/20 Needham
- Needham names Phathom Pharmaceuticals Top Pick for 2021
- 12/15/20 Needham
- Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
- 06/18/20 RBC Capital
- Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics - 02/03/21
- Travere Therapeutics price target raised to $48 from $33 at BMO Capital
- 02/03/21 Canaccord
- Travere Therapeutics price target raised to $51 from $28 at Canaccord
- 11/23/20 Evercore ISI
- Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics - 02/02/21
- Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study
- 01/11/21
- Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M
- 01/11/21
- Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M
- 02/05/21
- Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year
- 10/29/20
- Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year
- 10/27/20
- Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27)
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer reports Q4 adjusted EPS 42c, consensus 48c
- 02/01/21
- Notable companies reporting before tomorrow's open
- 11/10/20
- Passage Bio reports Q3 EPS (63c), consensus (76c)
- 08/13/20
- Passage Bio reports Q2 EPS (60c), consensus (57c)
ORTX Orchard Therapeutics - 11/03/20
- Orchard Therapeutics reports Q3 EPS (20c), consensus (46c)
- 01/11/21
- Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M
- 01/11/21
- Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M
- 11/05/20
- Invitae reports Q3 non-GAAP EPS (62c), consensus (66c)
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 08/10/20
- Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M
- 08/10/20
- Amicus reports Q2 EPS (20c), consensus (26c)
- 11/09/20
- Homology Medicines reports Q 3EPS (62c), consensus (80c)
- 08/10/20
- Homology Medicines reports Q2 EPS (78c), consensus (76c)
- 11/05/20
- Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year
- 11/05/20
- BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B
- 11/05/20
- BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29
- 11/05/20
- Avrobio reports Q3 EPS ($1.01), consensus (81c)
- 11/09/20
- Abeona Therapeutics reports Q3 EPS (8c), consensus (15c)
- 08/10/20
- Abeona Therapeutics reports Q2 EPS (14c), consensus (17c)
|
Conference/Events
|
17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< TVTX Travere Therapeutics - 02/02/21
- Ligand says entitled to $5.9M milestone on Travere application submission
- 01/12/21
- Travere Therapeutics receives orphan drug designation for sparsentan from FDA
- 01/11/21
- Travere Therapeutics announces anticipated upcoming milestones
- 11/30/20
- Travere Therapeutics completes patient enrollment in DUPLEX Study
TAK Takeda Pharmaceutical - 01/28/21
- Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion
- 01/21/21
- Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine
- 12/18/20
- Takeda confirms FDA approval of sNDA for Iclusig
- 12/16/20
- Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment
- 02/05/21
- Sanofi presents amended protocols in fitusiran clinical studies
- 01/27/21
- Sanofi's priority is to continue to develop two Covid vaccine candidates
- 01/27/21
- Sanofi to provide support to BioNTech in manufacturing Covid vaccine
- 01/25/21
- Nanobiotix to partner with Sanofi on gene therapy pipeline
SGTX Sigilon Therapeutics - 12/17/20
- Sigilon Therapeutics receives Orphan Drug designation for SIG-005
- 12/14/20
- Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19
- 01/21/21
- Ultragenyx announces FDA clearance of IND application for UX701
- 01/11/21
- Ultragenyx announces 2021 milestones
- 01/11/21
- Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31
- 01/11/21
- Ultragenyx sees 2021 Crysvita revenue $180M-$190M
- 02/08/21
- Longevity announces 4D trial collaboration with Pfizer and Merck KGaA
- 02/05/21
- Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027
- 02/02/21
- Pfizer sees FY21 revenue from BNT162b2 approximately $15B
- 02/01/21
- BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses
- 02/08/21
- Passage Bio's IND application for Krabbe disease candidate cleared by FDA
- 01/28/21
- Passage Bio annoounces FDA IND clearance for PBFT02
- 01/11/21
- Passage Bio says PBGM01 entering clinic to study safety, efficacy
- 01/11/21
- Passage Bio announces corporate outlook
ORTX Orchard Therapeutics - 02/05/21
- Orchard Therapeutics announces $150M strategic financing
- 01/29/21
- Orchard Therapeutics appoints Braden Parker as CCO
- 01/19/21
- Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN
- 01/14/21
- Orchard Therapeutics granted RMAT designation for OTL-200
- 12/31/20
- CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021
- 12/07/20
- CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval
- 11/11/20
- CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment
- 11/09/20
- Orphazyme submits arimoclomol MAA to EMA
- 01/13/21
- Pacific Biosciences, Invitae to develop genome sequencing platform
- 01/11/21
- Invitae falls -10.2%
- 12/17/20
- Invitae falls -7.4%
- 12/17/20
- Invitae introduces routine exome reanalysis
- 02/08/21
- Amicus announces preclinical Fabry disease gene therapy data
- 02/08/21
- Amicus reports 'positive' initial clinical data for CLN3 program
- 01/11/21
- Amicus announces 2021 upcoming milestones
- 01/11/21
- Amicus announces 2021 strategic priorities
- 02/08/21
- Homology reports first presentation of data from IND-enabling studies of HMI-203
- 01/12/21
- Pfizer invests $120M in four clinical-stage biotech companies
- 01/06/21
- Homology Medicines announces plans for three clinical programs in 2021
- 11/19/20
- Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer
- 01/20/21
- Denali Therapeutics CFO sells 50K shares of common stock
- 01/11/21
- Denali Therapeutics appoints Nancy Thornberry to board of directors
- 01/08/21
- Denali plans to file IND or CTA for DNL919 in late 2021/early 2022
- 01/08/21
- Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021
- 01/10/21
- BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study
- 12/21/20
- BioMarin reports results of Phase 3 extension study of vosoritide
- 11/17/20
- BioMarin and Deep Genomics enter into preclinical collaboration
- 11/09/20
- BioMarin expands clinical program for vosoritide with new studies
- 02/08/21
- Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi
- 01/19/21
- Avrobio appoints Diana Escolar as CMO
- 11/17/20
- Avrobio announces new data in clinical programs
- 10/05/20
- Avrobio to collaborate with University of Manchester for MPS II therapy
- 01/25/21
- Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting
- 12/21/20
- Abeona announces acceptance of late-breaker abstracts for WORLDSymposium
- 10/27/20
- Abeona Therapeutics names of Michael Amoroso as COO
- 10/06/20
- Abeona forms special committee to oversee strategic direction, leadership, ops
- 11/25/20 H.C. Wainwright
- Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
- 11/11/20 B. Riley
- Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
- 11/10/20 Cantor Fitzgerald
- Cantor upgrades Abeona to Overweight with shares trading near cash
- 11/10/20 Cantor Fitzgerald
- Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- 11/18/20 Mizuho
- Avrobio price target raised to $43 from $35 at Mizuho
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Avrobio initiated with a Buy at Berenberg
- 03/31/20 H.C. Wainwright
- Avrobio downgraded to Neutral from Buy at H.C. Wainwright
- 01/29/21 Jefferies
- Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
- 01/11/21 Baird
- BioMarin price target raised to $110 from $100 at Baird
- 12/21/20 Piper Sandler
- BioMarin data today should ease approvability concerns, says Piper Sandler
- 12/17/20 JPMorgan
- BioMarin remains 'highest conviction name' at JPMorgan
- 11/11/20 JPMorgan
- Denali Therapeutics price target raised to $65 from $45 at JPMorgan
- 11/11/20 H.C. Wainwright
- Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
- 11/10/20 Goldman Sachs
- Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
- 11/06/20 H.C. Wainwright
- Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
- 12/14/20 H.C. Wainwright
- Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
- 11/08/20 Oppenheimer
- Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
- 08/11/20 Oppenheimer
- Homology Medicines price target lowered to $27 from $32 at Oppenheimer
- 08/11/20 H.C. Wainwright
- Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
- 01/22/21 JPMorgan
- Amicus remains top idea into 'meaningful catalyst' at JPMorgan
- 01/04/21 Cowen
- Amicus could move 30%-40% on Pompe study data, says Cowen
- 12/28/20 Cantor Fitzgerald
- Amicus assumed with an Overweight at Cantor Fitzgerald
- 12/14/20 JPMorgan
- JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
- 02/08/21 JPMorgan
- Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
- 10/29/20 Morgan Stanley
- Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
- 10/28/20 JPMorgan
- Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
- 10/28/20 Deutsche Bank
- Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform on valuation at Oppenheimer
- 02/01/21 Oppenheimer
- Invitae downgraded to Perform from Outperform at Oppenheimer
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral on valuation at Ladenburg
- 11/06/20 Ladenburg
- Invitae downgraded to Neutral from Buy at Ladenburg
- 10/26/20 Guggenheim
- Orphazyme initiated with a Buy at Guggenheim
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
- 10/26/20 BofA
- Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics - 01/07/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 01/06/21 Cantor Fitzgerald
- Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
- 09/14/20 Oppenheimer
- Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
- 09/10/20 SMBC Nikko
- Orchard Therapeutics initiated with an Outperform at SMBC Nikko
- 02/04/21
- Fly Intel: Top five analyst initiations
- 02/04/21 Guggenheim
- Passage Bio initiated with a Buy at Guggenheim
- 01/25/21 Citi
- Citi upgrades Passage Bio to Buy after pullback and ahead of data
- 01/25/21 Citi
- Passage Bio upgraded to Buy from Neutral at Citi
- 02/04/21 DZ Bank
- Pfizer upgraded to Buy from Hold at DZ Bank
- 02/03/21 Mizuho
- Pfizer price target lowered to $42 from $44 at Mizuho
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 01/29/21 Piper Sandler
- Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
- 01/25/21 Credit Suisse
- Ultragenyx price target raised to $99 from $64 at Credit Suisse
- 01/11/21 Baird
- Ultragenyx price target raised to $165 from $110 at Baird
- 01/11/21 Barclays
- Ultragenyx price target raised to $176 from $121 at Barclays
- 01/08/21 Piper Sandler
- Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics - 12/29/20 Barclays
- Sigilon Therapeutics initiated with an Overweight at Barclays
- 12/29/20 Morgan Stanley
- Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
- 12/29/20 Jefferies
- Sigilon Therapeutics initiated with a Buy at Jefferies
- 02/05/21 Piper Sandler
- Piper reiterates Overweight on Kymera after Sanofi capital markets day
- 01/19/21 UBS
- Sanofi price target lowered to EUR 99 from EUR 100 at UBS
- 01/15/21 Deutsche Bank
- Sanofi initiated with a Sell at Deutsche Bank
- 01/08/21 Morgan Stanley
- Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical - 01/29/21 Morgan Stanley
- Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
- 12/29/20 Needham
- Needham names Phathom Pharmaceuticals Top Pick for 2021
- 12/15/20 Needham
- Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
- 06/18/20 RBC Capital
- Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics - 02/03/21
- Travere Therapeutics price target raised to $48 from $33 at BMO Capital
- 02/03/21 Canaccord
- Travere Therapeutics price target raised to $51 from $28 at Canaccord
- 11/23/20 Evercore ISI
- Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics - 02/02/21
- Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study
- 01/11/21
- Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M
- 01/11/21
- Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M
- 02/05/21
- Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year
- 10/29/20
- Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year
- 10/27/20
- Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27)
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer reports Q4 adjusted EPS 42c, consensus 48c
- 02/01/21
- Notable companies reporting before tomorrow's open
- 11/10/20
- Passage Bio reports Q3 EPS (63c), consensus (76c)
- 08/13/20
- Passage Bio reports Q2 EPS (60c), consensus (57c)
ORTX Orchard Therapeutics - 11/03/20
- Orchard Therapeutics reports Q3 EPS (20c), consensus (46c)
- 01/11/21
- Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M
- 01/11/21
- Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M
- 11/05/20
- Invitae reports Q3 non-GAAP EPS (62c), consensus (66c)
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 08/10/20
- Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M
- 08/10/20
- Amicus reports Q2 EPS (20c), consensus (26c)
- 11/09/20
- Homology Medicines reports Q 3EPS (62c), consensus (80c)
- 08/10/20
- Homology Medicines reports Q2 EPS (78c), consensus (76c)
- 11/05/20
- Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year
- 11/05/20
- BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B
- 11/05/20
- BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29
- 11/05/20
- Avrobio reports Q3 EPS ($1.01), consensus (81c)
- 11/09/20
- Abeona Therapeutics reports Q3 EPS (8c), consensus (15c)
- 08/10/20
- Abeona Therapeutics reports Q2 EPS (14c), consensus (17c)
|